Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.
Separately, Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $31.25.
Rhythm Pharmaceuticals stock opened at $19.46 on Friday. Rhythm Pharmaceuticals has a twelve month low of $16.80 and a twelve month high of $33.81.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Monday, March 12th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.14. sell-side analysts predict that Rhythm Pharmaceuticals will post -2.3 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $5,866,000. Opaleye Management Inc. purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $1,113,000. Perceptive Advisors LLC purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $21,654,000. ArrowMark Colorado Holdings LLC purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $13,487,000. Finally, Artal Group S.A. purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at $1,453,000. Institutional investors and hedge funds own 89.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/rhythm-pharmaceuticals-rytm-rating-increased-to-hold-at-bidaskclub.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.